Published on: February 25, 2022

Bringing drugs to market faster

Instem offers an opportunity to invest in a business with two specific attractions – (1) The group is exposed to a number of structural long-term growth markets – big pharma continues to develop and test steadily more drugs each year, and there is a growing use of technology to optimise and streamline this process; and (2) Instem has a strong position in the pre-Clinical (animal testing) phase of the drug development lifecycle, and is beginning to replicate this strength in other areas, most notably the recent d-wise acquisition with a focus on software and technology consulting in the Clinical trials segment. We believe that Instem will continue to deliver on an organic basis, but that its recent acquisitions will serve to dramatically expand the group’s reach and its long term potential.

Related Content